[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc (ACXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,589
  • Shares Outstanding, K 5,270
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,970 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta -2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.45
  • Number of Estimates 1
  • High Estimate $-0.45
  • Low Estimate $-0.45
  • Prior Year $-1.23
  • Growth Rate Est. (year over year) +63.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3100 +13.50%
on 08/14/26
1.8172 -18.18%
on 08/17/26
-0.0631 (-4.07%)
since 07/17/26
3-Month
1.3100 +13.50%
on 08/14/26
2.2200 -33.02%
on 05/22/26
-0.3931 (-20.91%)
since 05/19/26
52-Week
1.3100 +13.50%
on 08/14/26
8.3400 -82.17%
on 10/08/25
-3.5631 (-70.56%)
since 08/19/25

Most Recent Stories

More News
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

STATEN ISLAND, N.Y. , Aug. 17, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 1.4869 (+3.26%)
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

STATEN ISLAND, N.Y. , Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 1.4869 (+3.26%)
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

STATEN ISLAND, N.Y. , Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule...

ACXP : 1.4869 (+3.26%)
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

STATEN ISLAND, N.Y. , Aug. 10, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 1.4869 (+3.26%)
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

STATEN ISLAND, N.Y. , Aug. 3, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat...

ACXP : 1.4869 (+3.26%)
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection

STATEN ISLAND, N.Y. , July 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat...

ACXP : 1.4869 (+3.26%)
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update

STATEN ISLAND, N.Y. , July 8, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 1.4869 (+3.26%)
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

STATEN ISLAND, N.Y. , June 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...

ACXP : 1.4869 (+3.26%)
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / New to The Street's longtime featured biotechnology client, Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), highlighted a potentially transformative regulatory...

ACXP : 1.4869 (+3.26%)
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity

ACXP : 1.4869 (+3.26%)

Business Summary

Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y.

See More

Key Turning Points

3rd Resistance Point 1.8367
2nd Resistance Point 1.7433
1st Resistance Point 1.5917
Last Price 1.4869
1st Support Level 1.3467
2nd Support Level 1.2533
3rd Support Level 1.1017

See More

52-Week High 8.3400
Fibonacci 61.8% 5.6545
Fibonacci 50% 4.8250
Fibonacci 38.2% 3.9955
Last Price 1.4869
52-Week Low 1.3100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.